Global Retirement Partners LLC Raises Position in Thermo Fisher Scientific Inc. $TMO

Key Points

• Global Retirement Partners LLC boosted its Thermo Fisher Scientific stake by 121.1% in the fourth quarter, adding 3,955 shares to bring its total to 7,221 shares worth about $4.18 million.
• Thermo Fisher’s latest quarterly results beat expectations, with EPS of $5.44 versus $5.25 expected and revenue of $11.01 billion, up 6.2% year over year.
• The company announced a quarterly dividend of $0.47 per share, while analysts remain broadly positive with a consensus rating of Moderate Buy and an average price target of $616.10.

Global Retirement Partners LLC grew its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 121.1% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 7,221 shares of the medical research company's stock after purchasing an additional 3,955 shares during the period. Global Retirement Partners LLC's holdings in Thermo Fisher Scientific were worth $4,184,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently made changes to their positions in the business. Vanguard Group Inc. lifted its holdings in shares of Thermo Fisher Scientific by 0.9% during the 4th quarter. Vanguard Group Inc. now owns 34,133,702 shares of the medical research company's stock valued at $19,778,774,000 after purchasing an additional 288,296 shares during the last quarter. Capital World Investors lifted its holdings in shares of Thermo Fisher Scientific by 7.4% during the 3rd quarter. Capital World Investors now owns 10,285,145 shares of the medical research company's stock valued at $4,988,132,000 after purchasing an additional 706,572 shares during the last quarter. Franklin Resources Inc. lifted its holdings in shares of Thermo Fisher Scientific by 21.0% during the 3rd quarter. Franklin Resources Inc. now owns 5,925,671 shares of the medical research company's stock valued at $2,874,069,000 after purchasing an additional 1,028,125 shares during the last quarter. Bank of New York Mellon Corp lifted its holdings in shares of Thermo Fisher Scientific by 54.7% during the 3rd quarter. Bank of New York Mellon Corp now owns 3,571,857 shares of the medical research company's stock valued at $1,732,422,000 after purchasing an additional 1,262,967 shares during the last quarter. Finally, Massachusetts Financial Services Co. MA lifted its holdings in shares of Thermo Fisher Scientific by 5.1% during the 4th quarter. Massachusetts Financial Services Co. MA now owns 3,087,666 shares of the medical research company's stock valued at $1,789,148,000 after purchasing an additional 150,668 shares during the last quarter. Hedge funds and other institutional investors own 89.23% of the company's stock.

Thermo Fisher Scientific Stock Performance

NYSE TMO opened at $449.43 on Friday. The stock has a 50-day simple moving average of $481.20 and a two-hundred day simple moving average of $538.80. The firm has a market capitalization of $167.02 billion, a P/E ratio of 24.71, a PEG ratio of 2.00 and a beta of 0.88. Thermo Fisher Scientific Inc. has a fifty-two week low of $385.46 and a fifty-two week high of $643.99. The company has a debt-to-equity ratio of 0.77, a quick ratio of 1.15 and a current ratio of 1.53.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last released its quarterly earnings data on Thursday, April 23rd. The medical research company reported $5.44 earnings per share for the quarter, beating analysts' consensus estimates of $5.25 by $0.19. Thermo Fisher Scientific had a return on equity of 16.86% and a net margin of 15.15%.The business had revenue of $11.01 billion during the quarter, compared to analyst estimates of $10.86 billion. During the same quarter last year, the business posted $5.15 EPS. The company's revenue was up 6.2% on a year-over-year basis. Thermo Fisher Scientific has set its FY 2026 guidance at 24.640-25.120 EPS. On average, equities analysts forecast that Thermo Fisher Scientific Inc. will post 24.86 earnings per share for the current year.

Thermo Fisher Scientific Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, July 15th. Stockholders of record on Monday, June 15th will be given a dividend of $0.47 per share. The ex-dividend date is Monday, June 15th. This represents a $1.88 dividend on an annualized basis and a dividend yield of 0.4%. Thermo Fisher Scientific's dividend payout ratio (DPR) is 10.34%.

Insider Transactions at Thermo Fisher Scientific

In other news, CEO Marc N. Casper sold 5,000 shares of the firm's stock in a transaction dated Wednesday, March 4th. The stock was sold at an average price of $512.40, for a total transaction of $2,562,000.00. Following the sale, the chief executive officer directly owned 123,925 shares in the company, valued at $63,499,170. This trade represents a 3.88% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, COO Gianluca Pettiti sold 400 shares of the firm's stock in a transaction dated Monday, April 27th. The shares were sold at an average price of $462.66, for a total value of $185,064.00. Following the sale, the chief operating officer owned 25,051 shares in the company, valued at $11,590,095.66. This trade represents a 1.57% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.33% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

A number of equities analysts recently issued reports on TMO shares. Royal Bank Of Canada set a $490.00 target price on Thermo Fisher Scientific and gave the stock a "sector perform" rating in a research note on Thursday, May 14th. Citigroup raised their target price on Thermo Fisher Scientific from $660.00 to $685.00 and gave the stock a "buy" rating in a research note on Friday, January 30th. TD Cowen reduced their target price on Thermo Fisher Scientific from $696.00 to $683.00 and set a "buy" rating for the company in a research note on Friday, January 30th. Morgan Stanley restated an "overweight" rating and issued a $620.00 target price on shares of Thermo Fisher Scientific in a research note on Monday, April 27th. Finally, Weiss Ratings restated a "hold (c)" rating on shares of Thermo Fisher Scientific in a research note on Wednesday, April 8th. Two research analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and three have given a Hold rating to the stock. Based on data from MarketBeat.com, Thermo Fisher Scientific has a consensus rating of "Moderate Buy" and an average price target of $616.10.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific NYSE: TMO is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.